DrugBiological
Rozanolixizumab clinical trials
Also written UCB7665.
- studies test it
- 23
- open now
- 3
- in phase 3
- 12
- first study started
- 2014
Keep track of what changes. Save the rozanolixizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- UCB7665
- 15
Studies by the year they started
23 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 12
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 0
UCB Biopharma SRL (19) · UCB Biopharma S.P.R.L. (3) · UCB Celltech (1)
Studies
Open first, then newest update. How each study uses rozanolixizumab is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingPhase 3UCB Biopharma SRLNCT07463521Written as Rozanolixizumab
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingPhase 3UCB Biopharma SRLNCT07465289Written as Rozanolixizumab
- Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRecruitingPhase 4UCB Biopharma SRLNCT07246564Written as Rozanolixizumab
- An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingPhase 3UCB Biopharma SRLNCT06540144Written as rozanolixizumab
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedPhase 2/3UCB Biopharma SRLNCT06149559Written as rozanolixizumab
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active, not recruitingPhase 3UCB Biopharma SRLNCT05063162Written as Rozanolixizumab
- A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT04124965Written as Rozanolixizumab
- A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT03971422Written as Rozanolixizumab
- A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT04650854Written as Rozanolixizumab
- A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating WomenCompletedPhase 1UCB Biopharma SRLNCT06720714Written as Rozanolixizumab
- A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)CompletedPhase 3UCB Biopharma SRLNCT05681715Written as Rozanolixizumab
- A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia SyndromeCompletedPhase 2UCB Biopharma SRLNCT05643794Written as rozanolixizumab
- A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisTerminatedPhase 2UCB Biopharma SRLNCT04875975Written as Rozanolixizumab
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04200456Written as Rozanolixizumab
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy ParticipantsCompletedPhase 1UCB Biopharma SRLNCT04828343Written as rozanolixizumab
- A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04596995Written as Rozanolixizumab
- Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune ThrombocytopeniaCompletedPhase 2UCB Biopharma SRLNCT02718716Written as UCB7665
- A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04224688Written as Rozanolixizumab
- A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedPhase 2UCB Biopharma S.P.R.L.NCT03861481Written as Rozanolixizumab
- A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedPhase 2UCB Biopharma SRLNCT04051944Written as Rozanolixizumab
Codes
What other systems call rozanolixizumab · ClinicalTrials.gg INT000963
- MeSH (NLM) C000627812rozanolixizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P7186074QCROZANOLIXIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q120491843rozanolixizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152270RozanolixizumabOne source FDA
- DrugBank DB14919One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627812 | rozanolixizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P7186074QC | ROZANOLIXIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120491843 | rozanolixizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152270 | Rozanolixizumab | One source FDA |
| DrugBank | DB14919 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.